PULM Pulmatrix
- 1.890
- +0.030+1.61%
Pulmatrix News
Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Estimate, Sales $2.20M Beat $1.77M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by 45.19 percent. This is a 50 percent increase over losses of $(1.14) per s
Pulmatrix GAAP EPS of -$3.87, Revenue of $7.3M
Pulmatrix 2023 Research and Development Expenses $15.5M >PULM
Pulmatrix 2023 Research and Development Expenses $15.5M >PULM
Pulmatrix 2023 Rev $7.3M >PULM
Pulmatrix 2023 Rev $7.3M >PULM
Press Release: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update PR Newswire BEDFORD, Mass., March 28, 2024 2023 year-end $19.2 million cash and cash equivalents provide pro
Pulmatrix Shifts to Outsourced CMO Model, Terminates Executive
Pulmatrix to Present at Investor Conferences, Limits Updates
Express News | Pulmonx Sees FY24 Revenue $81M-$84M
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
By Ben Glickman Pulmatrix will close a study of a potential treatment for a fungal lung infection as it prioritizes limiting cash burn and pursuing strategic alternatives. The biopharmaceutical comp
Pulmatrix Stops PUR1900 Phase 2B Study Patient Enrollment And Closing Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Strategic Alternatives
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix Pu
Buy Rating for Pulmatrix: Potential of Ongoing Projects, Drug Formulations, and Strategic Partnerships
Pulmatrix GAAP EPS of -$1.03, Revenue of $1.75M
Pulmatrix Q3 EPS $(1.03) Beats $(1.05) Estimate, Sales $1.75M Miss $1.86M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by 1.9 percent. This is a 28.97 percent increase over losses of $(1.45) per
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M
09:09 AM EST, 11/09/2023 (MT Newswires) -- Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M
Pulmatrix 3Q Loss $3.77M >PULM
Pulmatrix 3Q Loss $3.77M >PULM
Press Release: Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire BEDFORD, Mass., Nov. 9, 2023 Patient enrollment for the Phase 2b study of PUR1900 is ongoing with
Global Aspergillosis Treatment Market Report 2023-2030 With Competitive Analysis of Pfizer, Merck, F2G, Novartis, Astellas, Bayer, Mayne Pharma, & PULMATRiX
The "Aspergillosis Treatment Market Size, Share & Trends Analysis Report By Type (Allergic, Chronic, Invasive), By Drug Class (Antifungal), By Route...
Pulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100
Pulmatrix Announces FDA Acceptance Of IND Application For PUR3100 To Treat Acute Migraine
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
BEDFORD, Mass., Sept. 19, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 (Dihydroergotamine Mesylate Inhalation Powder) in the Acute Treatment of Migraine. The PUR3100 formulation uses Pulmatrix's novel, proprietary dry powder delivery technology, iSPERSE to deliver DHE via oral inhalation using a dry powder inhaler.
Analysis
Price Target
No Data
